The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 328:81-86 January 14, 1993 Number 2
NextNext

A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the ß-Globin Disorders
Susan P. Perrine, Gordon D. Ginder, Douglas V. Faller, George H. Dover, Tohru Ikuta, H. Ewa Witkowska, Shi-ping Cai, Elliott P. Vichinsky, and Nancy F. Olivieri

 Sign up for free e-toc
 

This Article
-Full Text

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Fetal-globin ({gamma}-globin) chains inhibit the polymerization of hemoglobin S (sickle hemoglobin) and can functionally substitute for the {beta}-globin chains that are defective or absent in patients with the {beta}-thalassemias. Identifying safe mechanisms to stimulate fetal-hemoglobin production is therefore of great interest. Previous studies have shown that administering butyrate selectively stimulates the promoter of the human fetal-globin gene and leads to increases in {gamma}-globin-gene expression in the developing fetus, cultured cells, and animal models.

Methods To determine whether butyrate can stimulate fetal-globin production in humans, we treated three patients (3 to 13 years old) with sickle cell anemia and three patients (7 to 27 years old) with {beta}-thalassemia syndromes with a short course of intravenous infusions of arginine butyrate. The drug was infused continuously for either two or three weeks; the initial dose was 500 mg per kilogram of body weight per day. Globin-chain ratios, proportions of reticulocytes producing hemoglobin F (F reticulocytes), and levels of {gamma}-globin messenger RNA (mRNA) were determined before and during treatment.

Results In all six patients, fetal-globin synthesis increased by 6 to 45 percent above pretreatment levels (P<0.01). The proportion of F reticulocytes increased about twofold, and the level of {gamma}-globin mRNA increased twofold to sixfold. The increase in {gamma}-globin synthesis led to improvement in the globin-chain ratios in the patients with thalassemia. The treatment of one patient was extended for seven weeks, and her hemoglobin level increased from 4.7 to 10.2 g per deciliter (2.9 to 6.3 mmol per liter). Side effects were minimal; one patient had a transient increase in serum aminotransferase concentrations.

Conclusions In patients with {beta}-hemoglobinopathies butyrate, a natural fatty acid, can significantly and rapidly increase fetal-globin production to levels that can ameliorate {beta}-globin disorders. Further trials of this class of compounds are warranted to determine long-term tolerance and efficacy in patients with sickle cell anemia or {beta}-thalassemia.


Source Information

From the Children's Hospital Oakland Research Institute, Oakland, Calif. (S.P.P., H.E.W., E.P.V.); the Hospital for Sick Children, Toronto (N.F.O.); the University of Minnesota School of Medicine, Minneapolis (G.D.G.); Boston University School of Medicine, Boston (D.V.F.); Howard Hughes Medical Institute, University of California, San Francisco (T.I., S.C.); and Johns Hopkins University School of Medicine, Baltimore (G.H.D.).

Address reprint requests to Dr. Perrine at Children's Hospital Oakland Research Institute, Rm. 115, 747 52nd St., Oakland, CA 94609.

Full Text of this Article


Related Letters:

Butyrate Treatment in ß-Hemoglobinopathies
Brauer M., Al-Momen A.-K., Faller D. V., Olivieri N. F.
Extract | Full Text  
N Engl J Med 1995; 333:1287-1288, Nov 9, 1995. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.